Progenics Pharmaceuticals Inc.
Bedford, MA Lantheus Medical Imaging, Inc. Part of Lantheus Holdings, Inc.
- UEI
- YLYKVRPCTCR3
- CAGE
- 34KE9
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
-
Its parent company, Lantheus Holdings, Inc., ranks:
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Corporate family
-
-
Parent
Bedford, MA
XKLLNAJB6LJ6
-
Parent
Bedford, MA
XKLLNAJB6LJ6
- SAM.gov registration date
- Physical address
- 201 Burlington Rd, Bedford, MA 01730, USA
- Website
- lantheus.com
- Founded
- 1956
- Employees
- 251-1K
- Estimated annual revenue
- $100M-$250M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | -$133,123 |
| FY2026 | $33,755,559 |
| FY2025 | $34,869,098 |
| FY2024 | $27,114,076 |
| FY2023 | $26,000,245 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Veterans Affairs | $32,913,554 | |
| 2 | Department of Health and Human Services | $622,273 | |
| 3 | Defense Health Agency | $86,609 |
Contract vehicles
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Lantheus Medical Imaging, Inc. | Bedford, MA | 325412 Pharmaceutical Preparation Manufacturing |
| Nuclear Diagnostic Products, Inc. | Rockaway, NJ | 325412 Pharmaceutical Preparation Manufacturing |
| IBA Molecular | Sterling, VA | 325412 Pharmaceutical Preparation Manufacturing |
| Advanced Accelerator Applications USA Inc. | — | 325412 Pharmaceutical Preparation Manufacturing |
| GE Healthcare | Arlington Heights, IL | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc., supplies radiopharmaceutical diagnostic imaging agents—principally PYLARIFY (piflufolastat F-18)—to the federal government as a prime contractor, with all 227 recent awards held at the prime level and no subcontract footprint. The vendor is 100 percent owned by Lantheus Holdings, Inc., operates from North Billerica and Bedford, Massachusetts, and competes full-and-open across the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), a multi-agency vehicle administered by GSA. No SBA set-aside designations apply to the prime contracting footprint, though a small number of task orders carry total small business set-aside tags as issued by individual Veterans Integrated Service Networks.
Progenics' core federal work centers on supply of PYLARIFY, a positron emission tomography imaging agent used to detect and localize prostate cancer in diagnostic procedures. Representative work spans a $592.8 million Federal Supply Schedule contract effective April 1, 2025, through March 31, 2030, issued by the General Services Administration on behalf of the Pharmaceuticals and Drugs program; numerous single-award Blanket Purchase Agreements with individual Veterans Integrated Service Networks valued between $793.9 thousand and $9.29 million; and hundreds of firm fixed-price delivery orders and BPA calls placing task orders against those vehicles, typically $100 thousand to $5 million in individual ceiling value, issued by VISN medical centers and the NIH Clinical Center. A $1.211 million sole-source indefinite delivery contract awarded by the National Institute on Aging in September 2026 for NeuroSeq amyloid radiotracers to the Baltimore Longitudinal Study of Aging signals capability expansion beyond PYLARIFY into amyloid imaging reagents for Alzheimer's disease research. Recent representative orders include a $3.085 million delivery order from VISN 12 (September 2025, executing option year one through August 2027), a $9.057 million delivery order from VISN 5 (January 2026, through January 2031), a $5.719 million delivery order from VISN 7 (May 2022, through April 2027), and a $6.159 million delivery order from VISN 7 (December 2022, through December 2027).
Customer concentration sits overwhelmingly with the Department of Veterans Affairs. The top five customers account for 45 percent of award count but 84 percent of potential value, led by VISN 12's $611.6 million in combined potential value across 16 awards—reflecting the April 2025 FSS contract ceiling—followed by VISN 10 ($32.4 million, 30 awards), VISN 6 ($29.3 million, 22 awards), the NIH NIAID Acquisitions office ($28.6 million, 2 awards), and VISN 21 ($28.4 million, 18 awards). Activity has declined year over year—50 awards in 2022, 47 in 2023, 34 in 2024, 40 in 2025, and 22 through mid-2026—consistent with consolidation toward fewer, higher-ceiling master vehicles and call-downs against them. Twenty-six awards (combined potential value $47 million) complete within the next twenty-four months and face recompete exposure.
Progenics places all work under the Pharmaceuticals and Drugs FSS (199 task orders, $254 million combined potential value), supported by six single-award BPAs with Defense Health Agency and individual VISNs (245 thousand in ceiling value) and associated IDIQs spanning VISN procurement needs. The vendor operates as the sole authorized manufacturer of PYLARIFY for federal procurement, giving it a quasi-monopoly position within the federal healthcare system's prostate cancer imaging program. Recent sole-source procurement justifications have cited Progenics as the only responsible source under FAR 6.302-1, as in VISN 6's January 2025 IDIQ award ($5.99 million) and the National Institute on Aging's September 2026 NeuroSeq contract. Manufacturing and distribution are performed at facilities in North Billerica and Bedford, Massachusetts, with order fulfillment logistics supporting delivery to VA medical centers nationwide. Corporate structure places Progenics as a subsidiary within Lantheus Holdings, Inc.'s broader portfolio of diagnostic imaging and radiopharmaceutical products; the parent company holds the overarching Federal Supply Schedule contract and nominally anchors all federal healthcare relationships, though Progenics operates distinctly for federal contracting and customer-facing purposes.
Quick answers
Is Progenics Pharmaceuticals Inc. registered in SAM.gov?
Yes. Progenics Pharmaceuticals Inc.'s SAM.gov registration is active through January 8, 2027.
Which contract vehicles does Progenics Pharmaceuticals Inc. hold?
Progenics Pharmaceuticals Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
How much has Progenics Pharmaceuticals Inc. received in federal contracts?
Federal contracts obligated $34,869,098 to Progenics Pharmaceuticals Inc. in fiscal year 2025 and $121,605,856 in fiscal years 2023 through 2027.
How does Progenics Pharmaceuticals Inc. rank among federal contractors?
Progenics Pharmaceuticals Inc.'s parent company, Lantheus Holdings, Inc., ranked #14 in NAICS 325412, #16 in PSC 6505 and #18 in NAICS 3254 in FY2025.
What is Progenics Pharmaceuticals Inc.'s most recent federal award?
Progenics Pharmaceuticals Inc.'s most recent federal contract award is Neuraseq amyloid radiotracers for the baltimore longitudinal study of aging (75N98026F00001), from Office of Logisitics and Acquisition Operations (NIH), on September 22, 2026.
On GovTribe
See Progenics Pharmaceuticals Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors